<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-124789" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ixazomib</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Haq</surname>
            <given-names>Mawiyah</given-names>
          </name>
          <aff>St. George's, University of London Medical School, London, UK</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pellegrini</surname>
            <given-names>Mark V.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thumallapally</surname>
            <given-names>Nishitha</given-names>
          </name>
          <aff>Conway Medical Cancer Center, Duke Health Affiliate</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mawiyah Haq declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mark Pellegrini declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nishitha Thumallapally declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-124789.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ixazomib, a second-generation proteasome inhibitor, emerges as a pivotal therapeutic option&#x000a0;for managing&#x000a0;multiple myeloma. Addressing the needs of multiple myeloma patients, this activity discusses ixazomib's mechanism of action, indications, and contraindications. The comprehensive&#x000a0;discussion extends to ixazomib's adverse event profile and other critical facets, ensuring the&#x000a0;members&#x000a0;of an interprofessional team can navigate the complexities inherent in managing multiple myeloma and its associated conditions. The collaborative emphasis throughout underscores the indispensable nature of interprofessional teamwork in managing these intricate hematological conditions and the need to enhance&#x000a0;the team's knowledge and proficiency in leveraging ixazomib to benefit individuals affected by multiple myeloma and its related complexities.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate patient profiles and disease contexts where ixazomib is indicated for multiple myeloma treatment.</p></list-item><list-item><p>Differentiate between ixazomib and other therapeutic options, understanding its unique mechanisms, benefits, and potential drawbacks.</p></list-item><list-item><p>Implement evidence-based dosing strategies and treatment plans for ixazomib, ensuring proper administration and adherence.</p></list-item><list-item><p>Implement plans&#x000a0;with interprofessional teams, including oncologists, pharmacists, and nurses, to optimize ixazomib therapy within the broader patient care strategy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=124789&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=124789">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-124789.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ixazomib is an oral proteasome inhibitor used in the treatment of multiple myeloma.<xref ref-type="bibr" rid="article-124789.r1">[1]</xref>&#x000a0;Ixazomib is the first orally dosed second-generation proteasome inhibitor to receive FDA approval&#x000a0;and is used in combination with dexamethasone and lenalidomide in patients who have had prior treatment, allowing patients to be on a fully oral regimen, which has been proven to have a progression-free survival benefit.<xref ref-type="bibr" rid="article-124789.r2">[2]</xref><xref ref-type="bibr" rid="article-124789.r3">[3]</xref>&#x000a0;Ixazomib was approved based on the results&#x000a0;of the phase III TOURMALINE-MM1 study, a worldwide double-blind and randomized study done on patients with relapsed/refractory multiple myeloma.<xref ref-type="bibr" rid="article-124789.r3">[3]</xref></p>
        <p>
<bold>FDA Approved&#x000a0;Indications</bold>
</p>
        <p>Ixazomib is currently FDA-approved to treat relapsed or refractory multiple myeloma.</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Ixazomib&#x000a0;is sometimes prescribed off-label&#x000a0;to treat amyloidosis.<xref ref-type="bibr" rid="article-124789.r4">[4]</xref></p>
        <p>Ixazomib is also currently being studied in a phase II clinical trial involving patients with Waldenstrom macroglobulinemia.<xref ref-type="bibr" rid="article-124789.r5">[5]</xref>&#x000a0;Many studies are&#x000a0;underway with ixazomib for use in bladder cancer, T-cell lymphomas, and neuroblastomas; none have been approved yet.<xref ref-type="bibr" rid="article-124789.r6">[6]</xref><xref ref-type="bibr" rid="article-124789.r7">[7]</xref><xref ref-type="bibr" rid="article-124789.r8">[8]</xref></p>
      </sec>
      <sec id="article-124789.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Ixazomib falls under the drug class of proteasome inhibitors.&#x000a0;The drug is made up of an alanine leucine dipeptide core, and it is specifically a reversible inhibitor of the 26S proteasome and inhibits the chymotrypsin-like subunit of the proteasome.<xref ref-type="bibr" rid="article-124789.r9">[9]</xref><xref ref-type="bibr" rid="article-124789.r10">[10]</xref>&#x000a0;This action ultimately disrupts cellular homeostasis, leading to apoptosis of multiple myeloma cells sensitive or resistant to other conventional therapies.<xref ref-type="bibr" rid="article-124789.r11">[11]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>Following oral administration, ixazomib achieves maximum plasma concentration in 1 hour, with a mean oral bioavailability of 58%. The drug is highly protein-bound.</p>
        <p><bold>Distribution:</bold>&#x000a0;The steady-state volume of distribution of ixazomib is 543 L.</p>
        <p><bold>Metabolism:</bold>&#x000a0;The metabolism of ixazomib&#x000a0;appears to occur via CYP and non-CYP pathways, with no predominant CYP isozyme contribution. Non-cytochrome P450 (CYP)-mediated metabolism appears to be the major clearance mechanism for ixazomib.<xref ref-type="bibr" rid="article-124789.r10">[10]</xref> At higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions (decreasing order) of 3A4, 1A2, 2B6, 2C8, 2D6, 2C19, and 2C9.<xref ref-type="bibr" rid="article-124789.r12">[12]</xref></p>
        <p><bold>Elimination:&#x000a0;</bold>Ixazomib is eliminated mainly in the urine (62%) and the feces (22%). The drug has a terminal half-life of 9.5 days.</p>
      </sec>
      <sec id="article-124789.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Forms and Strengths</bold>
</p>
        <p>Ixazomib is available in oral capsule formulations of 2.3, 3, and 4 mg.&#x000a0;Ixazomib is orally dosed.&#x000a0;</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>The recommended dose is 4 mg&#x000a0;per dose.<xref ref-type="bibr" rid="article-124789.r11">[11]</xref>&#x000a0;Based on the drug approval study, it should be taken weekly on days 1, 8, and 15 of a 28-day cycle.<xref ref-type="bibr" rid="article-124789.r3">[3]</xref>&#x000a0;</p>
        <p>It is also important to remember that ixazomib&#x000a0;should be given with dexamethasone and lenalidomide, with specific dosing schedules within a cycle. Both ixazomib and dexamethasone are given on days 1, 8, and 15; it is important to separate them&#x000a0;since ixazomib should not be taken with food, whereas dexamethasone should be.<xref ref-type="bibr" rid="article-124789.r1">[1]</xref><xref ref-type="bibr" rid="article-124789.r11">[11]</xref></p>
        <p>Ixazomib should be taken either&#x000a0;2 hours after eating or&#x000a0;1 hour&#x000a0;before, with a full glass of water. The drug should be taken on the same day and hour of the week, and if a dose is missed, it should only be replaced if there are at least 72 hours till the next dose.<xref ref-type="bibr" rid="article-124789.r1">[1]</xref><xref ref-type="bibr" rid="article-124789.r11">[11]</xref></p>
        <p>
<bold>Special Patient Population</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Ixazumib requires dose adjustment in patients with renal impairment. For patients with bilirubin &#x0003e;1.5 times the upper normal limit, start dosing at 3 mg daily on days 1, 8, and 15 of a 28-day cycle.<xref ref-type="bibr" rid="article-124789.r13">[13]</xref></p>
        <p><bold>Renal impairment:&#x000a0;</bold>Renal impairment requires dose adjustment. For patients with a CrCl &#x0003c;30,&#x000a0;start dosing at 3 mg daily on days 1, 8, and 15 of a 28-day cycle.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>No human data is available; the risk of skeletal abnormalities, embryo-fetal toxicity, and reduced fetal weight exists based on animal studies. Clinicians should weigh the risks and benefits during pregnancy. Clinicians should obtain a pregnancy test before initiating treatment, and patients should avoid pregnancy using non-hormonal contraception methods during treatment and for 90 days following treatment cessation.</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Patients should avoid breastfeeding during treatment and for 90 days following treatment cessation.</p>
        <p><bold>Pediatric patients:&#x000a0;</bold>Ixazomib is not approved for use in pediatric patients.</p>
        <p><bold>Older patients:&#x000a0;</bold>Studies on older patients have shown that adding oral ixazomib to the standard treatment of lenalidomide and low-dose dexamethasone resulted in a clinically relevant progression-free survival benefit. However, this result&#x000a0;did not include patients older than 75.<xref ref-type="bibr" rid="article-124789.r14">[14]</xref></p>
      </sec>
      <sec id="article-124789.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse reactions seen with ixazomib are thrombocytopenia, neutropenia, nausea, vomiting, diarrhea, constipation, rash, peripheral neuropathy, peripheral edema, and back pain. These effects occurred in more than&#x000a0;20% of patients in the TOURMALINE MM1 study, with the most common severe adverse effects being thrombocytopenia and diarrhea.<xref ref-type="bibr" rid="article-124789.r1">[1]</xref>&#x000a0;Some of these adverse events can become serious, particularly hepatotoxicity, neuropathy, neutropenia, and thrombocytopenia, in addition to thrombotic microangiopathy,&#x000a0;thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome, and Stevens-Johnson syndrome.</p>
        <p>Different eye disorders were also seen in some patients taking ixazomib, including blurred vision, dry eyes, and conjunctivitis.<xref ref-type="bibr" rid="article-124789.r11">[11]</xref>&#x000a0;Furthermore, proteasome inhibitors are known to cause peripheral neuropathy, which was also seen with ixazomib. However, ixazomib caused fewer peripheral neuropathy cases than bortezomib, another proteasome inhibitor.<xref ref-type="bibr" rid="article-124789.r1">[1]</xref></p>
        <p>Regarding&#x000a0;nausea and vomiting that occurs with ixazomib, it was seen primarily in the first&#x000a0;3 months of treatment during the first cycle during the drug approval study. Antiemetics were&#x000a0;added to the regimen in some cases, and some patients also received prophylactic antiemetics. The first instance of diarrhea was also highest during the first&#x000a0;3 months of treatment, and the occurrence decreased as time passed. Antidiarrheal medications were given to some patients, loperamide being the most common. In terms of constipation that occurred in some patients, the use of opioids due to bone pain as a possible cause cannot be ruled out. Rashes that occurred using ixazomib were commonly erythematous, macular, or papular lesions or generalized eruptions. Like nausea and diarrhea, the emergence of rashes was highest during the first&#x000a0;3 months of treatment and was managed with antihistamines, steroids, or dose reduction.<xref ref-type="bibr" rid="article-124789.r15">[15]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Most drug interactions with ixazomib revolve around the effects of induced hepatic metabolism, leading to decreased levels of ixazomib. The list of such agents is long but includes bosentan, butalbital, carbamazepine, efavirenz, fosphenytoin, phenobarbital, phenytoin, and rifampin.</p>
      </sec>
      <sec id="article-124789.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are no specific contraindications to prescribing ixazomib. However, many warnings and precautions&#x000a0;are necessary&#x000a0;for patients taking&#x000a0;this drug. For example, ixazomib should not be prescribed alongside cytochrome P3A inducers. Also, female patients should not take ixazomib during pregnancy due to the possibility of harming the fetus.<xref ref-type="bibr" rid="article-124789.r16">[16]</xref></p>
        <p>Patients should avoid pregnancy while&#x000a0;taking ixazomib, and contraception should be used while using the drug, as well as for the&#x000a0;90 days&#x000a0;following the final dose of ixazomib. This measure applies to both males and females. Furthermore, due to the unknown effects of ixazomib on breast milk,&#x000a0;the drug should be avoided in breastfeeding women. More caution&#x000a0;is necessary for patients with renal or hepatic impairment as higher levels of ixazomib are circulating in the blood; clinicians should reduce the dose of ixazomib.&#x000a0;In older patients, ixazomib can be dosed normally, as research has shown no differences&#x000a0;between varying age populations. On the other hand, the safety and use of ixazomib in pediatric populations are unknown.<xref ref-type="bibr" rid="article-124789.r11">[11]</xref></p>
      </sec>
      <sec id="article-124789.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients on ixazomib&#x000a0;require close monitoring. Specifically, liver function tests need to be carried out periodically due to the risk of hepatotoxicity. There have been reports of patients taking&#x000a0;ixazomib&#x000a0;who experienced hepatic steatosis, hepatitis cholestatic, hepatocellular injury, and drug-induced liver injury. Hence, liver function must be monitored, and dose reductions must be made if necessary. Similarly, patients on ixazomib should have their platelets and absolute neutrophil count monitored monthly due to the risk of thrombocytopenia.</p>
        <p>During the first&#x000a0;3 cycles of treatment with ixazomib, the platelet count should be monitored weekly as drug levels will not be stable. Dose modification can be considered if any adverse effects occur regarding platelet or neutrophil count. Do not start the medication unless ANC &#x0003e;1000 and platelet count &#x0003e;75,000. Lastly, patients on ixazomib should be monitored for any signs of infection, as reactivation of herpes zoster virus has been reported in some patients. To avoid this, patients should receive prophylactic antivirals while on ixazomib.<xref ref-type="bibr" rid="article-124789.r1">[1]</xref><xref ref-type="bibr" rid="article-124789.r11">[11]</xref><xref ref-type="bibr" rid="article-124789.r15">[15]</xref></p>
      </sec>
      <sec id="article-124789.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Some of the toxicities involved with ixazomib include hematological and hepatic toxicities. Hematological toxicities include thrombocytopenia, which was seen primarily during the first&#x000a0;3 months of treatment in the drug approval study. Platelets usually drop after a dose of ixazomib and then rise again before the next treatment cycle. Also, during the study, a small percentage of patients had to be taken off of ixazomib therapy due to thrombocytopenia.<xref ref-type="bibr" rid="article-124789.r15">[15]</xref>&#x000a0;As previously discussed, there is also a risk of hepatotoxicity with ixazomib due to different hepatic injuries in patients; liver function monitoring is crucial.<xref ref-type="bibr" rid="article-124789.r11">[11]</xref></p>
        <p>Furthermore, unlike other proteasome inhibitors previously reported to cause cardiac toxicity, ixazomib is not known to cause an increase in cardiac events, toxicities, or prolonged QTc interval.<xref ref-type="bibr" rid="article-124789.r15">[15]</xref><xref ref-type="bibr" rid="article-124789.r17">[17]</xref>&#x000a0;Ixazomib is less neurotoxic than bortezomib and less cardiotoxic than carfilzomib.<xref ref-type="bibr" rid="article-124789.r2">[2]</xref></p>
      </sec>
      <sec id="article-124789.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Ixazomib is currently the only oral proteasome inhibitor being used in treating multiple myeloma, so all&#x000a0;interprofessional healthcare team members, including physicians, specialists, advanced practice practitioners, nursing staff, and pharmacists, should be aware of this drug, its indication, dosing, adverse event profile, potential drug-drug interactions, and requisite monitoring. Due to increasing use and the many adverse effects of ixazomib, the interprofessional team must monitor patients diligently, irrespective of their specific discipline.&#x000a0;</p>
        <p>Clinicians must remember to monitor patients' liver function tests and platelet and neutrophil counts. The healthcare&#x000a0;team should&#x000a0;coordinate their activities and share information for patients on ixazomib if they are experiencing any rashes, feeling unwell, diarrhea, or&#x000a0;other possible adverse reactions&#x000a0;that dose modifications or other therapeutic alterations can be made in time. This interprofessional approach will&#x000a0;increase the potential for patients to&#x000a0;achieve success with their triple therapy, including dexamethasone and lenalidomide, and optimize outcomes in multiple myeloma cases.</p>
      </sec>
      <sec id="article-124789.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=124789&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=124789">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/124789/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=124789">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-124789.s11">
        <title>References</title>
        <ref id="article-124789.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramirez</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma.</article-title>
            <source>J Adv Pract Oncol</source>
            <year>2017</year>
            <season>May-Jun</season>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>401</fpage>
            <page-range>401-405</page-range>
            <pub-id pub-id-type="pmid">30018846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richardson</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Zweegman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Laubach</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Raje</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Voorhees</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Skacel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Lonial</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ixazomib for the treatment of multiple myeloma.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>17</issue>
            <fpage>1949</fpage>
            <page-range>1949-1968</page-range>
            <pub-id pub-id-type="pmid">30422008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hanley</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Skacel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Venkatakrishnan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.</article-title>
            <source>Target Oncol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>643</fpage>
            <page-range>643-654</page-range>
            <pub-id pub-id-type="pmid">28803351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hughes</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Staron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanchorawala</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>A pharmacist's review of the treatment of systemic light chain amyloidosis.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>187</fpage>
            <page-range>187-198</page-range>
            <pub-id pub-id-type="pmid">33028132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castillo</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Meid</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Demos</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Guerrera</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kofides</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Munshi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsakmaklis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Treon</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstr&#x000f6;m macroglobulinemia: long-term follow-up.</article-title>
            <source>Blood Adv</source>
            <year>2020</year>
            <month>Aug</month>
            <day>25</day>
            <volume>4</volume>
            <issue>16</issue>
            <fpage>3952</fpage>
            <page-range>3952-3959</page-range>
            <pub-id pub-id-type="pmid">32822482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Woodfield</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment.</article-title>
            <source>Sci Rep</source>
            <year>2016</year>
            <month>Sep</month>
            <day>30</day>
            <volume>6</volume>
            <fpage>34397</fpage>
            <pub-id pub-id-type="pmid">27687684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boonstra</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Polk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hristov</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Kaminski</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Devata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.</article-title>
            <source>Am J Hematol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>92</volume>
            <issue>12</issue>
            <fpage>1287</fpage>
            <page-range>1287-1294</page-range>
            <pub-id pub-id-type="pmid">28842936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Asano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okubo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Isono</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Asano</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation.</article-title>
            <source>Cancer Sci</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>1194</fpage>
            <page-range>1194-1202</page-range>
            <pub-id pub-id-type="pmid">28342223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ghazarian</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luderer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kusdono</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Azab</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Spotlight on ixazomib: potential in the treatment of multiple myeloma.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2016</year>
            <volume>10</volume>
            <fpage>217</fpage>
            <page-range>217-26</page-range>
            <pub-id pub-id-type="pmid">26811670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hanley</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Labotka</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Venkatakrishnan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>431</fpage>
            <page-range>431-449</page-range>
            <pub-id pub-id-type="pmid">30117017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raedler</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.</article-title>
            <source>Am Health Drug Benefits</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>Spec Feature</issue>
            <fpage>102</fpage>
            <page-range>102-5</page-range>
            <pub-id pub-id-type="pmid">27668055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hanley</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Venkatakrishnan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bessudo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rasco</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Neil</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rowland Yeo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Esseltine</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Nemunaitis</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>180</fpage>
            <page-range>180-192</page-range>
            <pub-id pub-id-type="pmid">28800141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hanley</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Venkatakrishnan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Norris</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Nemunaitis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Falchook</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Labotka</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>82</volume>
            <issue>3</issue>
            <fpage>728</fpage>
            <page-range>728-38</page-range>
            <pub-id pub-id-type="pmid">27121262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harousseau</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Mohty</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Up-front ixazomib in older patients with myeloma.</article-title>
            <source>Blood</source>
            <year>2021</year>
            <month>Jul</month>
            <day>01</day>
            <volume>137</volume>
            <issue>26</issue>
            <fpage>3584</fpage>
            <page-range>3584-3586</page-range>
            <pub-id pub-id-type="pmid">34196682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moreau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mateos</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shustik</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Masszi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000e1;jek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Romeril</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Avivi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Liberati</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Minnema</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Einsele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lonial</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Esseltine</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.</article-title>
            <source>Br J Haematol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>178</volume>
            <issue>4</issue>
            <fpage>571</fpage>
            <page-range>571-582</page-range>
            <pub-id pub-id-type="pmid">28485007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kakimoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hoshino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hiraizumi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance.</article-title>
            <source>Intern Med</source>
            <year>2022</year>
            <month>May</month>
            <day>01</day>
            <volume>61</volume>
            <issue>9</issue>
            <fpage>1337</fpage>
            <page-range>1337-1343</page-range>
            <pub-id pub-id-type="pmid">34645759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124789.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hanley</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Diderichsen</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Labotka</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>van de Velde</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Venkatakrishnan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>105</volume>
            <issue>2</issue>
            <fpage>376</fpage>
            <page-range>376-387</page-range>
            <pub-id pub-id-type="pmid">29446068</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
